U.S. Senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at the start of a Senate hearing on the rising costs of prescription medicines.
Sanofi SA and Regeneron Pharmaceuticals Inc. will slash the U.S. list price of the companies’ potent but expensive cholesterol fighter Praluent by 60 percent.
U.S. drugmaker Pfizer Inc. said the company’s Chief Executive Albert Bourla plans to testify during February 2018 at a Senate hearing examining rising prescription drug prices.
A powerful U.S. Senate committee invited seven pharmaceutical companies to testify at a hearing during February 2019 examining rising prescription drug prices.
Healthcare stocks rallied with U.S. health insurers reaching record highs as results of the 2018 mid-term elections were seen reducing the likelihood of action to cut medical costs and programs in the world’s biggest and most profitable market.
The U.S. Senate overwhelmingly supported a new bill aimed at opioid abuse and other addictive drugs.
After multiple suspensions, the U.S. House of Representatives overwhelmingly voted to repeal a 2.3 percent tax on medical devices which is part of the Affordable Care Act that industry representatives believes has stifled innovation.
Five opioid manufacturers including OxyContin maker Purdue Pharma LP paid more than $10 million to advocacy groups and doctors tied to them, many of whom amplified industry messages supporting the use of the painkillers, a U.S. Senate report.
A U.S. Senate committee voted to move forward the nomination of Alex Azar, a former drug industry executive and lobbyist whom President Donald Trump has tapped to be the next secretary of Health and Human Services.
U.S. House Republicans proposed to delay or suspend several taxes under former President Barack Obama’s healthcare law, including a tax on medical devices and the so-called “Cadillac” tax on generous health insurance plans.